Related Experiment Video
Updated: Feb 7, 2026
07:39
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
25.2K
Dasatinib.
Markus Lindauer1, Andreas Hochhaus2
1Klinik für Innere Medizin III, Klinikum am Gesundbrunnen, Am Gesundbrunnen 20-24, 74078, Heilbronn, Germany. markus.lindauer@slk-kliniken.de.
Summary
Dasatinib effectively treats chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) by inhibiting BCR-ABL. While it induces rapid molecular remissions, these can be short-lived, and side effects require management.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Dasatinib is a potent oral tyrosine kinase inhibitor targeting BCR-ABL and other kinases.
- It is approved for treating chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Purpose of the Study:
- To review the preclinical and clinical activity of dasatinib.
- Focus on clinical studies evaluating dasatinib for CML treatment.
Main Methods:
- Review of preclinical data and clinical trials comparing dasatinib with imatinib.
- Analysis of efficacy in different phases of CML and Ph+ ALL.
- Evaluation of dosing, administration, and side effect profiles.
Main Results:
- First-line dasatinib demonstrates deeper and faster molecular remissions in CML compared to imatinib.
- Dasatinib induces hematologic and cytogenetic remissions in accelerated/blastic phase CML and Ph+ ALL, even after imatinib treatment.
- Remissions achieved with dasatinib may be transient; common side effects include cytopenias and pleural effusions.
Conclusions:
- Dasatinib is an effective treatment for CML and Ph+ ALL, offering significant remission rates.
- While effective, the durability of remissions and management of side effects are key considerations for dasatinib therapy.
